OBJECTIVE: To investigate the relative predictive value of CD4(+) metrics for serious clinical endpoints. DESIGN: Observational. METHODS: Patients (3012; 20 317 person-years) from control arms of ESPRIT and SILCAAT were followed prospectively. We used Cox regression to identify CD4(+) metrics (latest, baseline and nadir CD4(+) cell count, latest CD4(+)%, time spent with CD4(+) count below certain thresholds and CD4(+) slopes) independently predictive of all-cause mortality, non-AIDS deaths, non-AIDS (cardiovascular, hepatic, renal and non-AIDS malignancy) and AIDS events. Akaike information criteria (AIC) were calculated for each model. Significant metrics (P < 0.05) were then additionally adjusted for latest CD4(+) cell count. RESULTS: Non-AIDS deaths occurred at a higher rate than AIDS deaths [rate ratio: 6.48, 95% confidence interval (CI) 5.1-8.1], and non-AIDS events likewise (rate ratio: 1.72, 95% CI 1.65-1.79). Latest CD4(+) cell count was strongly predictive of lower risk of death (hazard ratio per log2 rise: 0.48, 95% CI 0.43-0.54), with lowest AIC of all metrics. CD4(+) slope over seven visits, after additional adjustment for latest CD4(+) cell count, was the only metric to be an independent predictor for all-cause (hazard ratio for slope <-10 cells/microl per month vs. 0 +/- 10: 3.04, 95% CI 1.98-4.67) and non-AIDS deaths (hazard ratio for slope <-10 cells/microl per month vs. 0 +/- 10: 2.62, 95% CI 1.62-4.22). Latest CD4(+) cell count (per log(2) rise) was the best predictor across all four endpoints and predicted hepatic (hazard ratio 0.46, 95% CI 0.33-0.63) and renal events (hazard ratio 0.39, 95% CI 0.21-0.70), but not cardiovascular events (hazard ratio 1.05, 95% CI 0.77-1.43) or non-AIDS cancers (hazard ratio 0.78, 95% CI 0.59-1.03). CONCLUSION: Latest CD4(+) cell count is the best predictor of serious endpoints. CD4(+) slope independently predicts all-cause and non-AIDS deaths.
OBJECTIVE: To investigate the relative predictive value of CD4(+) metrics for serious clinical endpoints. DESIGN: Observational. METHODS:Patients (3012; 20 317 person-years) from control arms of ESPRIT and SILCAAT were followed prospectively. We used Cox regression to identify CD4(+) metrics (latest, baseline and nadir CD4(+) cell count, latest CD4(+)%, time spent with CD4(+) count below certain thresholds and CD4(+) slopes) independently predictive of all-cause mortality, non-AIDS deaths, non-AIDS (cardiovascular, hepatic, renal and non-AIDS malignancy) and AIDS events. Akaike information criteria (AIC) were calculated for each model. Significant metrics (P < 0.05) were then additionally adjusted for latest CD4(+) cell count. RESULTS:Non-AIDS deaths occurred at a higher rate than AIDS deaths [rate ratio: 6.48, 95% confidence interval (CI) 5.1-8.1], and non-AIDS events likewise (rate ratio: 1.72, 95% CI 1.65-1.79). Latest CD4(+) cell count was strongly predictive of lower risk of death (hazard ratio per log2 rise: 0.48, 95% CI 0.43-0.54), with lowest AIC of all metrics. CD4(+) slope over seven visits, after additional adjustment for latest CD4(+) cell count, was the only metric to be an independent predictor for all-cause (hazard ratio for slope <-10 cells/microl per month vs. 0 +/- 10: 3.04, 95% CI 1.98-4.67) and non-AIDS deaths (hazard ratio for slope <-10 cells/microl per month vs. 0 +/- 10: 2.62, 95% CI 1.62-4.22). Latest CD4(+) cell count (per log(2) rise) was the best predictor across all four endpoints and predicted hepatic (hazard ratio 0.46, 95% CI 0.33-0.63) and renal events (hazard ratio 0.39, 95% CI 0.21-0.70), but not cardiovascular events (hazard ratio 1.05, 95% CI 0.77-1.43) or non-AIDS cancers (hazard ratio 0.78, 95% CI 0.59-1.03). CONCLUSION: Latest CD4(+) cell count is the best predictor of serious endpoints. CD4(+) slope independently predicts all-cause and non-AIDS deaths.
Authors: Jens D Lundgren; Abdel Babiker; Wafaa El-Sadr; Sean Emery; Birgit Grund; James D Neaton; Jacquie Neuhaus; Andrew N Phillips Journal: J Infect Dis Date: 2008-04-15 Impact factor: 5.226
Authors: Alan R Lifson; Waldo H Belloso; Cate Carey; Richard T Davey; Daniel Duprez; Wafaa M El-Sadr; Jose M Gatell; Daniela C Gey; Jennifer F Hoy; Eric A Krum; Ray Nelson; Daniel E Nixon; Nick Paton; Court Pedersen; George Perez; Richard W Price; Ronald J Prineas; Frank S Rhame; James Sampson; John Worley Journal: HIV Clin Trials Date: 2008 May-Jun
Authors: D Abrams; Y Lévy; M H Losso; A Babiker; G Collins; D A Cooper; J Darbyshire; S Emery; L Fox; F Gordin; H C Lane; J D Lundgren; R Mitsuyasu; J D Neaton; A Phillips; J P Routy; G Tambussi; D Wentworth Journal: N Engl J Med Date: 2009-10-15 Impact factor: 91.245
Authors: Antonella d'Arminio Monforte; Donald Abrams; Christian Pradier; Rainer Weber; Peter Reiss; Fabrice Bonnet; Ole Kirk; Matthew Law; Stephane De Wit; Nina Friis-Møller; Andrew N Phillips; Caroline A Sabin; Jens D Lundgren Journal: AIDS Date: 2008-10-18 Impact factor: 4.632
Authors: Lewis H Kuller; Russell Tracy; Waldo Belloso; Stephane De Wit; Fraser Drummond; H Clifford Lane; Bruno Ledergerber; Jens Lundgren; Jacqueline Neuhaus; Daniel Nixon; Nicholas I Paton; James D Neaton Journal: PLoS Med Date: 2008-10-21 Impact factor: 11.069
Authors: Barbara S Taylor; Yuanyuan Liang; L Sergio Garduño; Elizabeth A Walter; Margit B Gerardi; Gregory M Anstead; Delia Bullock; Barbara J Turner Journal: J Acquir Immune Defic Syndr Date: 2014-02-01 Impact factor: 3.731
Authors: Amit C Achhra; Amanda Mocroft; Michael Ross; Lene Ryom-Nielson; Anchalee Avihingsanon; Elzbieta Bakowska; Waldo Belloso; Amanda Clarke; Hansjakob Furrer; Gregory M Lucas; Matti Ristola; Mohammed Rassool; Jonathan Ross; Charurut Somboonwit; Shweta Sharma; Christina Wyatt Journal: Int J Antimicrob Agents Date: 2017-06-28 Impact factor: 5.283
Authors: Aditi Shendre; Marguerite R Irvin; Bradley E Aouizerat; Howard W Wiener; Ana I Vazquez; Kathryn Anastos; Jason Lazar; Chenglong Liu; Roksana Karim; Nita A Limdi; Mardge H Cohen; Elizabeth T Golub; Degui Zhi; Robert C Kaplan; Sadeep Shrestha Journal: Atherosclerosis Date: 2014-01-30 Impact factor: 5.162
Authors: Jason V Baker; W Keith Henry; Pragna Patel; Timothy J Bush; Lois J Conley; Wendy J Mack; E Turner Overton; Matt Budoff; John Hammer; Charles C Carpenter; Howard N Hodis; John T Brooks Journal: Clin Infect Dis Date: 2011-08-22 Impact factor: 9.079
Authors: Robert C Kalayjian; Bryan Lau; Rhoderick N Mechekano; Heidi M Crane; Benigno Rodriguez; Robert A Salata; Zipporah Krishnasami; James H Willig; Jeffrey N Martin; Richard D Moore; Joseph J Eron; Mari M Kitahata Journal: AIDS Date: 2012-09-24 Impact factor: 4.177
Authors: Amit C Achhra; Janaki Amin; Caroline Sabin; Haitao Chu; David Dunn; Lewis H Kuller; Joseph A Kovacs; David A Cooper; Sean Emery; Matthew G Law Journal: AIDS Date: 2012-08-24 Impact factor: 4.177
Authors: Trevor A Hart; Brian Mustanski; Daniel T Ryan; Pamina M Gorbach; Ron D Stall; Pamela J Surkan; Michael Plankey Journal: Arch Sex Behav Date: 2014-03-27